After-Hours Stock Movers 09/09: (ISEE) (AFRM) (KPLT) Higher; (APLS) (COOK) (ZUMZ) Lower (more...)

Iveric bio (ISEE): APLS Data As Good As Possible for Iveric, Buy Here - Analyst

Late Thursday, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) reported top-line results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

OAKS study met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively, compared to pooled sham at 12 months

DERBY did not meet the primary endpoint of GA lesion growth,... More

Affirm Holdings Inc. (AFRM) PT Raised to $110 at DA Davidson

DA Davidson analyst Christopher Brendler raised the price target on Affirm Holdings Inc. (NASDAQ: AFRM) to $110.00 (from $85.00) while maintaining a Neutral rating.

Affirm Holdings Inc. (AFRM) PT Raised to $82 at Jefferies

Jefferies analyst Ryan Carr raised the price target on Affirm Holdings Inc. (NASDAQ: AFRM) to $82.00 (from $56.00) while maintaining a Hold rating.

American Outdoor Brands Inc. (AOUT) PT Lowered to $35 at Wedbush

Wedbush analyst James Hardiman lowered the price target on American Outdoor Brands Inc. (NASDAQ: AOUT) to $35.00 (from $38.00) while maintaining a Outperform rating.

Iveric Bio (ISEE) PT Raised to $21 at Wedbush

Wedbush analyst David Nierengarten raised the price target on Iveric Bio (NASDAQ: ISEE) to $21.00 (from $16.00) while maintaining an Outperform rating.

"In our opinion the Phase 3 results announced by APLS (Neutral, Laura Chico) represent a best-case scenario for ISEE shares," the analyst commented.

Wedbush Downgrades Apellis Pharmaceuticals (APLS) to Neutral

Wedbush analyst Laura Chico downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Outperform to Neutral with a price target of $39.00 (from $71.00).

The analyst commented, "Our prior upgrade was predicated on the pivotal DERVY/OAKS studies holding a high probability of success (>80%) for at least the monthly... More

Apellis Pharmaceuticals (APLS) PT Lowered to $65 at Oppenheimer

Oppenheimer analyst Justin Kim lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $65.00 (from $80.00) while maintaining an Outperform rating.

The analyst commented, "On 9/9, Apellis reported mixed top-line results from its Phase 3 DERBY and OAKS studies (n=1,258) of pegcetacoplan in geographic... More

Apellis Pharmaceuticals (APLS) PT Lowered to $70 at Needham & Company

Needham & Company analyst Joseph Stringer lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $70.00 (from $85.00) while maintaining a Buy rating.

The analyst commented, "APLS announced yesterday results from the Ph3 DERBY and OAKS trials evaluating pegcetacoplan in Geographic Atrophy (GA). The... More

Iveric Bio (ISEE) PT Raised to $25 at Cowen; APLS Data Disclosure 'As Good As Possible for Iveric'

Cowen analyst Ken Cacciatore raised the price target on Iveric Bio (NASDAQ: ISEE) to $25.00 (from $15.00) while maintaining an Outperform rating, saying the data from competitor APLS is as good as possible for the company.

The analyst commented, "The APLS results could not... More

Sumo Logic Inc. (SUMO) PT Lowered to $25 at Cowen

Cowen analyst J. Derrick Wood lowered the price target on Sumo Logic Inc. (NASDAQ: SUMO) to $25.00 (from $27.00) while maintaining an Outperform rating.

The analyst commented, "2Q billings growth of 29% was ahead of Street at 26%, aided by upside from its large customer.... More

Zscaler (ZS) PT Raised to $315 at BMO Capital

BMO Capital analyst Keith Bachman raised the price target on Zscaler (NASDAQ: ZS) to $315.00 (from $250.00) while maintaining an Outperform rating.

The analyst commented, "We believe the quarters highlights include ST billings growth accelerating by 10 points and CRPO growth accelerating by 8 points on relatively... More

Apellis Pharmaceuticals (APLS) PT Lowered to $69 at BMO Capital, Overall Data 'Should Still be Enough'

BMO Capital analyst Matthew Luchini lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $69.00 (from $89.00) while maintaining an Outperform rating, saying the "totality of data plus the unmet need in GA provides reasonable basis for approval and recommend taking advantage of current... More

Zscaler (ZS) PT Raised to $320 at Mizuho Securities

Mizuho Securities analyst Gregg Moskowitz raised the price target on Zscaler (NASDAQ: ZS) to $320.00 (from $280.00) while maintaining a Buy rating following strong results.

The analyst commented, "ZS reported a very strong F4Q, as billings growth of 70% materially exceeded consensus expectations of low... More

Affirm Holdings Inc. (AFRM) PT Raised to $119 at BofA Securities

BofA Securities analyst Jason Kupferberg raised the price target on Affirm Holdings Inc. (NASDAQ: AFRM) to $119.00 (from $82.00) while maintaining a Buy rating.

The analyst commented, "Consistent with our bullish thesis, Affirm (AFRM)s F4Q print and F22 guidance reflect increased momentum in the... More

Piper Sandler Downgrades Sumo Logic Inc. (SUMO) to Neutral

Piper Sandler analyst Rob Owens downgraded Sumo Logic Inc. (NASDAQ: SUMO) from Overweight to Neutral with a price target of $20.00 (from $24.00).

The analyst comments "In an environment where software 'beats and raises' have become the norm, we are modestly lowering our forward... More

Stifel Starts Iveric Bio (ISEE) at Buy

Stifel analyst Annabel Samimy initiates coverage on Iveric Bio (NASDAQ: ISEE) with a Buy rating and a price target of $22.00.

The analyst comments "We are initiating coverage of IVERIC bio (ISEE) with a Buy rating and a 12-month target price of... More